​

Medpace (MEDP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MEDP Stock Forecast

Medpace (MEDP) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $562.00, with a high of $655.00 and a low of $425.00. This represents a -5.78% decline from the last price of $596.48.

$300 $380 $460 $540 $620 $700 High: $655 Avg: $562 Low: $425 Last Closed Price: $596.48

MEDP Stock Rating

Medpace stock's rating consensus is Hold, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (18.75%), 10 Hold (62.50%), 3 Sell (18.75%), and 0 Strong Sell (0.00%).

Hold
Total 16 3 10 3 0 Strong Sell Sell Hold Buy Strong Buy

MEDP Price Target Upside V Benchmarks

TypeNameUpside
StockMedpace-5.78%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks6.76%

Price Target Trends

1M3M12M
# Anlaysts556
Avg Price Target$564.60$564.60$525.50
Last Closing Price$596.48$596.48$596.48
Upside/Downside-5.34%-5.34%-11.90%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-173-11
Sep, 25-273-12
Aug, 25-282113
Jul, 25-211--13
Jun, 25-210--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 27, 2025Jailendra SinghTruist Financial$555.00$605.20-8.29%-6.95%
Oct 24, 2025Robert W. Baird$613.00$596.612.75%2.77%
Oct 24, 2025Mizuho Securities$655.00$597.459.63%9.81%
Oct 17, 2025Mizuho Securities$575.00$521.2110.32%-3.60%
Oct 02, 2025Barclays$425.00$543.90-21.86%-28.75%
Mar 24, 2025Michael ChernyLeerink Partners$330.00$330.59-0.18%-44.68%
Oct 23, 2024Eric ColdwellRobert W. Baird$349.00$326.546.88%-41.49%
Sep 25, 2024David WindleyJefferies$345.00$355.82-3.04%-42.16%
Aug 01, 2024Jailendra SinghTruist Financial$415.00$382.528.49%-30.43%
Jul 08, 2024Eric ColdwellRobert W. Baird$469.00$404.1316.05%-21.37%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2025Cowen & Co.SellSellhold
Oct 02, 2025BarclaysCautiousUnderweightdowngrade
Sep 09, 2025JefferiesHoldHoldhold
Jul 23, 2025Cowen & Co.BuySelldowngrade
Jun 24, 2025BarclaysOutperformCautiousinitialise
Apr 22, 2025William BlairMarket Performdowngrade
Oct 22, 2024Cowen & Co.BuyBuyhold
Sep 27, 2024UBSBuyNeutraldowngrade
Sep 25, 2024JefferiesBuyHolddowngrade
May 29, 2024Cowen & Co.Buyinitialise

Financial Forecast

EPS Forecast

$0 $4 $8 $12 $16 $20 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.07$5.06$7.57$9.20$13.06----
Avg Forecast$3.74$4.78$6.97$8.64$11.94$12.52$14.32$16.54$18.08
High Forecast$3.87$4.94$7.34$8.97$12.02$12.68$15.97$17.31$18.76
Low Forecast$3.57$4.56$6.85$8.63$11.84$12.28$13.57$15.84$17.75
Surprise %8.82%5.86%8.61%6.48%9.38%----

Revenue Forecast

$500M $1B $2B $2B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$925.92M$1.14B$1.46B$1.89B$2.11B----
Avg Forecast$912.22M$1.14B$1.45B$1.89B$2.11B$2.21B$2.46B$2.76B$3.14B
High Forecast$935.90M$1.17B$1.51B$1.94B$2.17B$2.22B$2.48B$2.76B$3.23B
Low Forecast$879.22M$1.10B$1.43B$1.86B$2.08B$2.20B$2.43B$2.75B$3.09B
Surprise %1.50%-0.04%0.56%-0.02%0.12%----

Net Income Forecast

$100M $200M $300M $400M $500M $600M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$144.93M$181.39M$245.21M$282.81M$404.39M----
Avg Forecast$127.25M$159.74M$178.50M$282.62M$379.75M$403.41M$458.58M$527.76M$575.69M
High Forecast$152.70M$191.68M$214.20M$339.14M$382.61M$403.71M$508.54M$551.09M$597.27M
Low Forecast$101.80M$127.79M$142.80M$226.10M$376.88M$390.88M$432.23M$504.43M$565.27M
Surprise %13.89%13.56%37.38%0.07%6.49%----

MEDP Forecast FAQ

Is Medpace stock a buy?

Medpace stock has a consensus rating of Hold, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 10 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Medpace is a neutral investment for most analysts.

What is Medpace's price target?

Medpace's price target, set by 16 Wall Street analysts, averages $562 over the next 12 months. The price target range spans from $425 at the low end to $655 at the high end, suggesting a potential -5.78% change from the previous closing price of $596.48.

How does Medpace stock forecast compare to its benchmarks?

Medpace's stock forecast shows a -5.78% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the diagnostics & research stocks industry (6.76%).

What is the breakdown of analyst ratings for Medpace over the past three months?

  • October 2025: 0% Strong Buy, 9.09% Buy, 63.64% Hold, 27.27% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 16.67% Buy, 58.33% Hold, 25.00% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 15.38% Buy, 61.54% Hold, 15.38% Sell, 7.69% Strong Sell.

What is Medpace’s EPS forecast?

Medpace's average annual EPS forecast for its fiscal year ending in December 2025 is $12.52, marking a -4.13% decrease from the reported $13.06 in 2024. Estimates for the following years are $14.32 in 2026, $16.54 in 2027, and $18.08 in 2028.

What is Medpace’s revenue forecast?

Medpace's average annual revenue forecast for its fiscal year ending in December 2025 is $2.21B, reflecting a 4.62% increase from the reported $2.11B in 2024. The forecast for 2026 is $2.46B, followed by $2.76B for 2027, and $3.14B for 2028.

What is Medpace’s net income forecast?

Medpace's net income forecast for the fiscal year ending in December 2025 stands at $403.41M, representing a -0.24% decrease from the reported $404.39M in 2024. Projections indicate $458.58M in 2026, $527.76M in 2027, and $575.69M in 2028.